104 related articles for article (PubMed ID: 9049528)
1. Economic aspects of captopril treatment.
Tsevat J; Pfeffer MA; Goldman L; Lee TH
Eur Heart J; 1997 Jan; 18(1):165. PubMed ID: 9049528
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness analysis and clinical practice.
Rector TS; Francis GS
J Am Coll Cardiol; 1995 Oct; 26(4):920-1. PubMed ID: 7560618
[No Abstract] [Full Text] [Related]
3. [Cost effectiveness of captopril after myocardial infarct; comment].
Szucs T; Berger K; Schulte-Hillen J; Kleber FX
Med Klin (Munich); 1996 Feb; 91(2):112-8. PubMed ID: 8850108
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of captopril therapy after myocardial infarction.
Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
[TBL] [Abstract][Full Text] [Related]
5. [Economical treatment of heart failure].
Sonntag F
Med Klin (Munich); 1996 Feb; 91(2):111. PubMed ID: 8850107
[No Abstract] [Full Text] [Related]
6. Valsartan, captopril, or both in myocardial infarction.
Moshenyat R; Kupfer Y; Tessler S
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988935
[No Abstract] [Full Text] [Related]
7. Valsartan, captopril, or both in myocardial infarction.
Jorde UP
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988936
[No Abstract] [Full Text] [Related]
8. [AT(1) blocker for post-infarct therapy. VALIANT Study].
Hasenfuss G
Internist (Berl); 2004 Aug; 45(8):946-8. PubMed ID: 15252713
[No Abstract] [Full Text] [Related]
9. Economic aspects of treatment with captopril after MI.
Davie AP; McMurray JJ
Eur Heart J; 1996 May; 17(5):648-50. PubMed ID: 8737090
[No Abstract] [Full Text] [Related]
10. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
[TBL] [Abstract][Full Text] [Related]
11. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
[TBL] [Abstract][Full Text] [Related]
12. Effects of early treatment with captopril and metoprolol singly or together on six-month mortality and morbidity after acute myocardial infarction. Results of the RIMA (Rimodellamento Infarto Miocardico Acuto) study. The RIMA researchers.
Coletta C; Ricci R; Ceci V; Seccareccia F; Rulli F; Mazzuca V; Putini RL; Salustri A; Bottero G; Pasquale M
G Ital Cardiol; 1999 Feb; 29(2):115-24; discussion 125-9. PubMed ID: 10088066
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of an early ACE-inhibitor treatment of patients with acute myocardial infarction: results of the 3 year follow-up period on 696 Swiss patients randomized to the ISIS-4 trial. ISIS-Switzerland Study Group.
Genoni M; Malacrida R; Sessa F; Siegrist P; Maggioni AP; Moccetti T
Z Kardiol; 2000 Feb; 89(2):81-3. PubMed ID: 10768275
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure.
Szucs TD
Am J Hypertens; 1997 Oct; 10(10 Pt 2):272S-279S. PubMed ID: 9366284
[TBL] [Abstract][Full Text] [Related]
15. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
MMW Fortschr Med; 2003 Dec; 145(49):18-9. PubMed ID: 14963986
[No Abstract] [Full Text] [Related]
16. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
17. Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies.
Borghi C; Omboni S; Reggiardo G; Bacchelli S; Esposti DD; Ambrosioni E;
BMC Cardiovasc Disord; 2018 Jun; 18(1):112. PubMed ID: 29866077
[TBL] [Abstract][Full Text] [Related]
18. Effects of captopril on ventricular arrhythmias in the early and late phase of suspected acute myocardial infarction. Randomized, placebo-controlled substudy of ISIS-4.
Budaj A; Cybulski J; Cedro K; Karczmarewicz S; Maciejewicz J; Wiśniewski M; Ceremuzyński L
Eur Heart J; 1996 Oct; 17(10):1506-10. PubMed ID: 8909907
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.
Dong FB; Sorensen SW; Manninen DL; Thompson TJ; Narayan V; Orians CE; Gregg EW; Eastman RC; Dasbach EJ; Herman WH; Newman JM; Narva AS; Ballard DJ; Engelgau MM
Pharmacoeconomics; 2004; 22(15):1015-27. PubMed ID: 15449965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]